La cadena de opciones muestra datos clave de las opciones de acciones de Meituan a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Meituan..

Meituan (OTC:MPNGY) Bolsa, Cadena de Opciones

Meituan is the largest food delivery service in China, with a 70.7% share of the market in 2020 per the Chinese government. For the year ended 2023, the firm generated 58% of revenue from on-demand services, 17% from hotel booking, coupon sales, advertising, and 25% from new initiatives. In the long term, its new initiatives business may transform the company into an all-encompassing grocer and logistics business involving community group buying, nonfood delivery, and online grocery, overtaking food delivery as its main business.

Meituan

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) with a Buy and maintains $33 price target.

News

Price Target

Analyst Ratings

EYPT

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) sees Q1 sales of $33.000 million-$35.000 million vs $35.38 million analyst estimate.

Guidance

ASUR

Asure Software Sees Q1 Sales $33.000M-$35.000M vs $35.38M Est

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) affirms FY2025 sales outlook from $134.00 million-$138.00 million to $134.00 million-$138.00 million vs $134.65 million estimate.

Asure Software Affirms FY2025 Sales Guidance of $134.00M-$138.00M vs $134.65M Est

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.18 by 16.67 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $30.79 million which missed the analyst consensus estimate of $30.80 million by 0.04 percent. This is a 17.24 percent increase over sales of $26.26 million the same period last year.

Earnings

Earnings Misses

Asure Software Q4 Adj EPS $0.15 Misses $0.18 Estimate, Sales $30.79M Miss $30.80M Estimate

The company's outlook is based on its best assessment of the current macroeconomic environment and related headwinds to consumer spending, including, but not limited to, inflationary pressures, tariffs, supply chain disruptions and foreign currency volatility.
 &nbsp;

Gap Expects FY25 Net Sales Growth Of 1% - 2% And Flat To Up Slightly For Q1

Macquarie analyst Paul Golding maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Outperform and maintains $110 price target.

Macquarie Maintains Outperform on Block, Maintains $110 Price Target

BigBear.ai Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) released its fourth-quarter results after Thursday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/03/b44179893/bigbear-ai-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-outlook">from the report. </a>
The Details: BigBear.ai reported quarterly losses of 43 cents per share, which missed the analyst consensus estimate for losses of five cents. Quarterly revenue came in at $43.8 million, which missed the analyst consensus estimate of $54.48 million and is an increase over sales of $40.56 million from the same period last year.
Gross margin was 37.4% in the fourth quarter of 2024 as compared to 32.1% in the fourth quarter of 2023. Ending backlog was $418 million as of Dec. 31, 2024, an increase of $250 million or 2.5 times ending backlog as of Dec. 31, 2023.
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/03/44172028/trade-turmoil-oil-slides-whats-driving-markets-thursday">Trade Turmoil, Oil Slides: What&#8217;s Driving Markets Thursday?</a>&nbsp;
&#8220;2024 was a pivotal year for the business. We demonstrated momentum through major contract wins, expanding our backlog and growing our pipeline, maturing our technology portfolio, and restructuring our debt to strengthen our financial position for the long term. These efforts were driven by strong execution from our team,&#8221; said Kevin McAleenan, CEO of&nbsp;BigBear.ai.
Outlook:&nbsp;The company expects fiscal 2025 revenue in a range of $160 million to $180 million. 
BBAI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, BigBear.ai shares were down 5.48% after-hours at $3.97 after falling 12.5% in regular trading Thursday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Tech

BBAI

BigBear.ai Stock Plummets After Q4 EPS, Revenues Miss: Details

Tigress Financial analyst Ivan Feinseth maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Buy and raises the price target from $64 to $70.

Tigress Financial Maintains Buy on Travel+Leisure, Raises Price Target to $70

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) has outperformed the market over the past 15 years by 6.14% on an annualized basis producing an average annual return of 17.41%. Currently, Constellation Brands has a market capitalization of $32.34 billion. 
Buying $100 In STZ: If an investor had bought $100 of STZ stock 15 years ago, it would be worth $1,130.45 today based on a price of $178.95 for STZ at the time of writing.
<h3>Constellation Brands's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741297509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.60 by 33.33 percent. This is a 370.59 percent increase over earnings of $0.17 per share from the same period last year. The company reported $480.90 million in sales this quarter. This is a 6.16 percent increase over sales of $453.00 million the same period last year.

Earnings Beats

Valhi Q4 EPS $0.80 Beats $0.60 Estimate, Sales $480.90M Up From $453.00M YoY

Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) reported quarterly earnings of $0.20 per share. This is a 148.78 percent increase over losses of $(0.41) per share from the same period last year. The company reported $174.35 million in sales this quarter. This is a 4.20 percent decrease over sales of $182.00 million the same period last year.

LOMA

Loma Negra Cia Industria Q4 GAAP EPS $0.20 Up From $(0.41) YoY, Sales $174.35M Down From $182.00M YoY

Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) reported quarterly losses of $(1.81) per share. This is a 15.1 percent increase over losses of $(2.13) per share from the same period last year. The company reported $5.65 million in sales this quarter. This is a 28.46 percent decrease over sales of $7.89 million the same period last year.

MOLN

Molecular Partners FY EPS $(1.81) Up From $(2.13) YoY, Sales $5.65M Down From $7.89M YoY

Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported financial results for the second quarter after the market close on Thursday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/03/g44179751/costco-wholesale-corporation-reports-second-quarter-and-year-to-date-operating-results-for-fiscal-">of the report</a>.
Q2 Earnings: Costco reported second-quarter revenue of $62.72 billion, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $63.13 billion. The membership-based retailer reported second-quarter adjusted earnings of $4.02 per share, missing analyst estimates of $4.10 per share, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Net sales for the second quarter were up 9.1% year-over-year. Comparable sales in the second quarter were up 8.3% in the U.S., up 4.6% in Canada and up 1.7% in the Other International segment. Total comps climbed 6.8%, and total e-commerce sales increased by 20.9%.
Costco noted that net sales in February totaled $19.81 billion, up 8.8% on a year-over-year basis. Net sales for the first 26 weeks of the year were up 8.3% year-over-year.
Membership fees came in at $1.19 billion, up from $1.11 billion in the prior year&#8217;s quarter. Costco raised the price of its annual store membership by five dollars in September 2024, marking the company&#8217;s first membership price hike since 2017.
Costco said it operates 897 warehouses, including 617 in the U.S. The company ended the quarter with $12.36 billion in cash and cash equivalents, up from $9.91 billion at the end of the first quarter.
Costco executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
COST Price Action: <a href="http://benzinga.com/quote/cost" target="_blank" rel="noreferrer noopener">Costco shares</a> were down 1.08% after-hours, trading at $1,015.50 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Check This Out: 
 • <a href="https://www.benzinga.com/government/regulations/25/03/44171377/retailers-warn-of-price-increases-due-to-trump-tariffs-as-consumer-health-concerns-persist">Retailers Warn Of Price Increases Due To Trump Tariffs As Consumer Health Concerns Persist</a>
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Costco Q2 2025 Earnings Call &#x7C; $COST" width="500" height="281" src="https://www.youtube.com/embed/WkgBSeubzs0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

COST

Costco Q2 Earnings: Revenue Beat, EPS Miss, Comps Up 6.8% Driven By Strength In The US

Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 89.47 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $115.89 million which missed the analyst consensus estimate of $119.46 million by 3.00 percent. This is a 15.71 percent decrease over sales of $137.48 million the same period last year.

SWBI

Smith & Wesson Brands Q3 Adj $0.02, Inline, Sales $115.89M Miss $119.46M Estimate

CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $(0.20) by 215 percent. This is a 2200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $38.09 million which beat the analyst consensus estimate of $19.42 million by 96.19 percent. This is a 43.17 percent increase over sales of $26.61 million the same period last year.

CTMX

CytomX Therapeutics Q4 GAAP EPS $0.23 Beats $(0.20) Estimate, Sales $38.09M Beat $19.42M Estimate

WIIM

ASLE

AerSale shares are trading higher after the company reported better-than-expected Q4 revenue results.

GWRE

Guidewire Raises FY25 Total Revenue Outlook From $1.155B - $1.167B To $1.164B - $1.174B, Est $1.162B

Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) reported quarterly losses of $(5.37) per share which missed the analyst consensus estimate of $(3.62) by 48.34 percent. This is a 656.34 percent decrease over losses of $(0.71) per share from the same period last year.

CDTX

Cidara Therapeutics Q4 2024 GAAP EPS $(5.37) Misses $(3.62) Estimate

ELEV

Elevation Oncology Q4 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate

Graphjet Technology ("Graphjet" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, today announced that it received a notice ("Notice") on February 28, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that, as a result of (i) the Company's delay in filing its Quarterly Report on Form 10-K for the period ended September 30, 2024&nbsp; (the "Initial Delinquent Filing") with the Securities and Exchange Commission (the "SEC"), and (ii) the Company's delay in filing its Annual Report on Form 10-Q for the period ended December 31, 2024 (the "Second Delinquent Filing"), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule").
The Notice has no immediate effect on the listing or trading of the Company's ordinary shares on the Nasdaq Global Market. The Notice states that the Company has 60 calendar days, or until April 29, 2025, to submit a plan to regain compliance with the Listing Rule with respect to the delinquent reports. If Nasdaq accepts the Company's plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date of the Initial Delinquent Filing, or until July 14, 2025, to regain compliance.

Comments

Meituan

Meituan (MPNGY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL